ARWR
Price
$79.90
Change
-$2.10 (-2.56%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
11.55B
44 days until earnings call
Intraday BUY SELL Signals
BMRN
Price
$56.78
Change
+$0.88 (+1.57%)
Updated
Jun 23, 04:03 PM (EDT)
Capitalization
10.8B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARWR vs BMRN

ARWR vs BMRN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARWR vs. BMRN commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and BMRN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (ARWR: $81.97 vs. BMRN: $55.89)
Brand notoriety: ARWR: Notable vs. BMRN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 89% vs. BMRN: 137%
Market capitalization -- ARWR: $11.55B vs. BMRN: $10.8B
ARWR [@Biotechnology] is valued at $11.55B. BMRN’s [@Biotechnology] market capitalization is $10.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 0 FA rating(s) are green whileBMRN’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 0 green, 5 red.
  • BMRN’s FA Score: 1 green, 4 red.
According to our system of comparison, ARWR is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while BMRN’s TA Score has 6 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 3 bearish.
  • BMRN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than BMRN.

Price Growth

ARWR (@Biotechnology) experienced а +6.25% price change this week, while BMRN (@Biotechnology) price change was +0.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 06, 2026.

BMRN is expected to report earnings on Aug 04, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($11.5B) has a higher market cap than BMRN($10.8B). ARWR has higher P/E ratio than BMRN: ARWR (48.72) vs BMRN (40.21). ARWR YTD gains are higher at: 23.467 vs. BMRN (-5.957). BMRN has higher annual earnings (EBITDA): 482M vs. ARWR (-134.47M). BMRN has more cash in the bank: 2.22B vs. ARWR (1.78B). ARWR has less debt than BMRN: ARWR (989M) vs BMRN (1.44B). BMRN has higher revenues than ARWR: BMRN (3.24B) vs ARWR (622M).
ARWRBMRNARWR / BMRN
Capitalization11.5B10.8B106%
EBITDA-134.47M482M-28%
Gain YTD23.467-5.957-394%
P/E Ratio48.7240.21121%
Revenue622M3.24B19%
Total Cash1.78B2.22B80%
Total Debt989M1.44B69%
FUNDAMENTALS RATINGS
ARWR vs BMRN: Fundamental Ratings
ARWR
BMRN
OUTLOOK RATING
1..100
2769
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9987
PRICE GROWTH RATING
1..100
3553
P/E GROWTH RATING
1..100
3410
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMRN's Valuation (82) in the Biotechnology industry is in the same range as ARWR (91). This means that BMRN’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as BMRN (100). This means that ARWR’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's SMR Rating (87) in the Biotechnology industry is in the same range as ARWR (99). This means that BMRN’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is in the same range as BMRN (53). This means that ARWR’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's P/E Growth Rating (10) in the Biotechnology industry is in the same range as ARWR (34). This means that BMRN’s stock grew similarly to ARWR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRBMRN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
55%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 19 days ago
58%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 6 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signal:
Gain/Loss:
BMRN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTOR0.710.04
+6.59%
Citius Oncology Inc
RDY13.910.62
+4.67%
Dr. Reddy's Laboratories Ltd
DHC8.930.07
+0.79%
Diversified Healthcare Trust
RBB25.490.01
+0.04%
RBB Bancorp
BPYPO15.31N/A
N/A
Brookfield Property Partners LP

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
+2.19%
AXON - BMRN
42%
Loosely correlated
-3.16%
IBO - BMRN
42%
Loosely correlated
+5.95%
VRDN - BMRN
40%
Loosely correlated
+6.01%
ARWR - BMRN
39%
Loosely correlated
+0.18%
PCVX - BMRN
37%
Loosely correlated
+1.30%
More